Breastcancer is the second leading cancer in women and it remains a key public healthconcern and a tremendous burden worldwide with an estimation of 1.7 million newcases reported each year globally. In 2015 approximately 560,000 patients dieddue to breast cancer of which 90% of the cases were of metastatic breast cancer(MBC). Among the patients diagnosed with MBC 70%-80% of the tumors wherehormone receptor-positive (HR-positive) MBCs.
Hormonaltherapy remains a foundation to treat HR-positive MBC, but clinical decisionsare becoming more challenging owing to heterogeneity, rapid evolvement of thetumors, and resistance to current endocrine treatments. There’s an unprecedentednumber of treatments available aiming in prolonging the outcome and optimizingthe quality of life before selecting vigorous regimes. Sequential single-agentendocrine and new endocrine-combination therapies provide significant criticalimprovements for long-term management of patients in the first line treatment.